Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Acute Care Syndromic Testing Market Growth in 2025?
In recent times, the market size of acute care syndromic testing has experienced a fast-paced growth. It is projected to expand from $4.08 billion in 2024 to an estimate of $4.62 billion in 2025 with a compound annual growth rate (CAGR) of 13.2%. Factors such as increased awareness about antimicrobial resistance, a surge in government financing for infectious diseases, greater investment in healthcare infrastructure, a heightened focus on syndromic testing, telemedicine expansion and a rise in infectious diseases are known to have contributed to the growth during the historic period.
What Is the Forecast for the Acute Care Syndromic Testing Market Size Through 2029?
The market size for acute care syndromic testing is anticipated to surge dramatically in the coming years. It is on track to reach a worth of $7.50 billion by 2029, advancing at a compound annual growth rate (CAGR) of 12.9%. The predicted growth in this timeframe can be credited to an increase in infectious disease cases, a surging need for prompt diagnostic solutions, growth in healthcare services, higher utilization of multiplex syndromic panels, and an expanding elderly population. The future trend will see a shift towards point-of-care testing, the incorporation of cloud-based platforms, the usage of multiplex panels, the creation of AI-powered tools, and the automation in syndromic testing.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp
What are the Key Market Players in Acute Care Syndromic Testing Market and How They’re Evolving?
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.
What Are the Primary Growth Drivers in the Acute Care Syndromic Testing Market?
The increasing occurrence of infectious diseases is projected to drive the growth of the acute care syndromic testing market. These diseases are caused by harmful microorganisms including bacteria, viruses, fungi, and parasites that can be transmitted among individuals, from animals, or the environment. Factors catalyzing the heightened incidence of infectious diseases include population growth, urbanization, global travel, resistance to antimicrobials, and climate change, thereby amplifying the demand for efficient prevention and treatment methods. Infectious diseases utilize acute care syndromic testing to swiftly detect pathogens and co-infections via multiplex molecular diagnostics, hence enabling targeted treatment options. As an example, the Health Security Agency, a government agency based in the UK, reported that in the fourth week of February 2024, the positivity rate of influenza rose to 16.6%, a growth from 14.0% in the preceding week. Consultations related to Influenza-like illness (ILI) also experienced an increase, escalating to 9.8 per 100,000 people compared to 7.5 per 100,000 in the previous week. Furthermore, admissions to the hospital due to influenza rose to 7.63 per 100,000, from 5.12 per 100,000 the week before. Thus, the escalating occurrence of infectious diseases is fuelling the acute care syndromic testing market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp
What Are the Leading Segments in the Global Acute Care Syndromic Testing Industry?
The acute care syndromic testing market covered in this report is segmented –
1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases
What Are the Key Market Trends in the Acute Care Syndromic Testing Industry?
In the acute care syndromic testing market, key players are driving innovation through developments in technologies such as multiplex real-time PCR, aiming to optimize diagnostic precision, hasten the discovery of pathogens, simplify lab procedures, shorten response time, and uplift patient results via immediate, accurate treatments. Multiplex real-time PCR technology represents a pioneering molecular diagnostic tool that allows for simultaneous detection and measurement of various pathogens or genetic targets within one PCR reaction, thereby accelerating and refining disease diagnosis. For instance, Netherlands-founded biotech research company QIAGEN N.V introduced the QIAstat-Dx syndromic testing solution in Japan in April 2023, designed with a SARS-CoV-2 respiratory panel capable of identifying more than 20 pathogens from a single sample. Utilizing multiplex real-time PCR technology, the system returns swift results with considerably less effort than stand-alone PCR tests. By the close of 2022, over 3,500 units of the system had been implemented worldwide, aiding in the diagnosis of respiratory, gastrointestinal, and meningitis-related diseases. The system is available in more than 100 nations, thus facilitating global access to syndromic testing.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report
What Is the Regional Outlook for the Acute Care Syndromic Testing Market?
North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21078
This Report Delivers Insight On:
1. How big is the acute care syndromic testing market, and how is it changing globally?
2. Who are the major companies in the acute care syndromic testing market, and how are they performing?
3. What are the key opportunities and risks in the acute care syndromic testing market right now?
4. Which products or customer segments are growing the most in the acute care syndromic testing market?
5. What factors are helping or slowing down the growth of the acute care syndromic testing market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model